Dlin-MC3-DMA: Ionizable Cationic Liposome for Potent mRNA and siRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is a chemically defined ionizable cationic lipid essential for advanced lipid nanoparticle (LNP) siRNA and mRNA delivery systems [APExBIO]. Its pH-responsive charge facilitates endosomal escape, maximizing cytoplasmic delivery of nucleic acids (Rafiei et al., 2025). Dlin-MC3-DMA achieves approximately 1000-fold higher potency in hepatic gene silencing versus its precursor lipids, with low ED50 values in mouse and non-human primate models. It is widely cited for roles in immunomodulation, mRNA vaccine formulation, and cancer immunochemotherapy. Storage, solubility, and workflow parameters are tightly defined to ensure experimental reproducibility (product).

Biological Rationale

The delivery of therapeutic nucleic acids such as siRNA and mRNA requires specialized carrier systems due to rapid degradation and poor cellular uptake of naked RNA. Ionizable cationic lipids, including Dlin-MC3-DMA, form the cornerstone of modern LNPs, enabling efficient encapsulation and protection of nucleic acids (Rafiei et al., 2025). These lipids are engineered to remain neutral at physiological pH (7.4), minimizing toxicity and off-target effects. In acidic endosomal compartments (pH ~5.5–6.5), they become protonated, gaining a positive charge that promotes endosomal membrane disruption and release of cargo into the cytoplasm. Dlin-MC3-DMA, along with helper lipids like DSPC, cholesterol, and PEG-DMG, composes the LNPs used in both preclinical and clinical nucleic acid therapies. This strategy is transformative for hepatic gene silencing, vaccine delivery, and immunomodulatory interventions [see also: Dlin-MC3-DMA: Optimizing LNP siRNA Delivery], expanding upon previous reports by detailing mechanisms and quantitative benchmarks.

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA is an ionizable amino lipid that transitions between neutral and cationic states depending on environmental pH. At physiological pH, its neutral charge limits systemic toxicity. Upon endocytosis, the acidic endosomal environment protonates its tertiary amine, imparting a positive charge. This change facilitates interactions with the anionic endosomal membrane, promoting destabilization and endosomal escape. As a result, siRNA or mRNA cargo is released into the cytoplasm, enabling gene silencing or expression. The efficiency of this process underpins Dlin-MC3-DMA’s exceptional potency for hepatic gene silencing and immunomodulation (Rafiei et al., 2025). Dlin-MC3-DMA is insoluble in water and DMSO but readily dissolves in ethanol at concentrations ≥152.6 mg/mL, facilitating its use in LNP formulation workflows. Its physicochemical profile is critical for reproducible nanoparticle assembly and functional delivery (APExBIO).

Evidence & Benchmarks

• Dlin-MC3-DMA-enabled LNPs achieved a 1000-fold increase in hepatic Factor VII gene silencing potency compared to DLin-DMA (ED50: 0.005 mg/kg in mice) (APExBIO).
• ED50 for transthyretin (TTR) gene silencing was 0.03 mg/kg in non-human primates, demonstrating robust cross-species efficacy (APExBIO).
• LNPs containing Dlin-MC3-DMA enabled efficient mRNA delivery and immunomodulation in microglial cells, as validated by morphometric and cytokine profiling in vitro and in iPSC-derived human microglia (Rafiei et al., 2025, Fig. 2–4).
• Machine learning models (MLP neural networks) successfully predicted LNP transfection efficiency and microglial phenotype modulation based on Dlin-MC3-DMA LNP formulations, with F1-scores ≥0.8 (Rafiei et al., 2025, Table 1).
• Dlin-MC3-DMA LNPs are standard components in COVID-19 mRNA vaccine and cancer immunochemotherapy research (Rafiei et al., 2025).

Applications, Limits & Misconceptions

Dlin-MC3-DMA is a validated siRNA delivery vehicle and mRNA drug delivery lipid in both preclinical and clinical settings. It is critical for hepatic gene silencing, as well as tissue-targeted mRNA delivery for immunomodulation (e.g., microglial repolarization). The lipid's neutral-to-cationic pH transition underpins its safety and efficacy profile. Despite these advantages, Dlin-MC3-DMA is not universally optimal for all cell types or tissues. It shows reduced efficiency in certain non-hepatic targets and may require additional targeting ligands (e.g., HA modification) for enhanced specificity, as demonstrated in machine learning-guided LNP design studies (Rafiei et al., 2025). For further discussion on predictive design and benchmarking in translational research, see Dlin-MC3-DMA and the Predictive Frontier, which this article extends by providing quantitative, cross-species benchmarks and workflow guidance.

Common Pitfalls or Misconceptions

• Dlin-MC3-DMA is not water or DMSO soluble: It must be dissolved in ethanol at ≥152.6 mg/mL for LNP preparation (APExBIO).
• Not a universal delivery agent: Potency is highest in hepatic and some immune cells; performance in other tissues may require additional targeting strategies (Rafiei et al., 2025).
• Requires strict cold storage: Store at -20°C or below; solutions degrade rapidly at higher temperatures (APExBIO).
• Misconception: Charge switching is not instantaneous; pH must be carefully controlled during formulation and application (Dlin-MC3-DMA: Ionizable Cationic Liposome—this article clarifies workflow parameters).
• Not suitable for naked administration: Requires formulation with helper lipids (DSPC, cholesterol, PEG-DMG) for LNP assembly and function (APExBIO).

Workflow Integration & Parameters

Dlin-MC3-DMA is supplied by APExBIO as a high-purity reagent (SKU: A8791). For LNP formulation, dissolve in ethanol and combine with helper lipids (DSPC, cholesterol, PEG-DMG) at optimized molar ratios (generally 50:10:38.5:1.5 mol% for MC3:DSPC:cholesterol:PEG-lipid). Solutions should be freshly prepared and used promptly. The recommended storage temperature is -20°C or below. LNP assembly is commonly achieved via rapid microfluidic mixing, producing nanoparticles 60–100 nm in diameter. The pH of the aqueous phase is typically maintained at 4.0 during formulation to ensure protonation and efficient nucleic acid encapsulation. Final LNPs are dialyzed or buffer-exchanged into physiological pH (7.4) buffer prior to in vivo use. For detailed troubleshooting and workflow optimization, refer to Dlin-MC3-DMA: Optimizing LNP siRNA Delivery, which this article updates with recent machine learning-guided design insights.

Conclusion & Outlook

Dlin-MC3-DMA remains a gold standard for constructing ionizable cationic liposome-based LNPs for potent siRNA and mRNA delivery. Its pH-responsive mechanism, high potency in hepatic gene silencing, and proven role in immunomodulatory applications are supported by robust experimental and computational evidence. Future developments will likely focus on rational LNP design—using approaches such as machine learning—to further tailor delivery and immunomodulation across diverse cell types. For the latest product specifications and ordering, consult the Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) product page from APExBIO.